CREB1 and colorectal carcinoma: Another report showed that astragaloside (AS-IV) can inhibit the epithelial–mesenchymal transition in CRC by inducing miR-134 expression, which significantly downregulates the CREB1 (a transcription factor) signaling pathway, thereby improving chemotherapy sensitivity [111].